MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Up 15.7%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares traded up 15.7% on Thursday . The stock traded as high as $2.68 and last traded at $2.43. 4,685,065 shares traded hands during trading, an increase of 99% from the average session volume of 2,353,060 shares. The stock had previously closed at $2.10.

MIRA Pharmaceuticals Trading Down 10.7 %

The company has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.03. The firm has a market cap of $32.07 million and a PE ratio of -3.24.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, equities research analysts anticipate that MIRA Pharmaceuticals, Inc. will post -0.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Large investors have recently modified their holdings of the stock. Praetorian Wealth Management Inc. acquired a new position in shares of MIRA Pharmaceuticals during the 1st quarter valued at $30,000. Cross Staff Investments Inc acquired a new position in shares of MIRA Pharmaceuticals in the 1st quarter valued at about $422,000. Suncoast Equity Management acquired a new position in shares of MIRA Pharmaceuticals in the first quarter worth $44,000. Finally, Virtu Financial LLC lifted its holdings in shares of MIRA Pharmaceuticals by 330.2% during the 1st quarter. Virtu Financial LLC now owns 63,055 shares of the company’s stock valued at $69,000 after buying an additional 48,397 shares during the last quarter. Institutional investors own 35.16% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.